The kinase drug discovery field is at a pivotal moment, with recent breakthroughs from industry leaders such as Biogen, A-Alpha Bio, and Proxygen paving the way for exciting new approaches in targeting kinases, particularly in targeted protein degradation.

However, with ongoing challenges including selectivity and resistance in small molecule inhibitors, the 3rd Kinase Targeted Drug Discovery Summit helped you overcome these hurdles that limit the therapeutic applications and call for in-depth discussions focused on innovative future strategies for kinase targeted drugs.

What did you miss?

• Discovering cutting-edge developments in small molecule therapeutics, including PROTACs, molecular glues, and allosteric inhibitors
• Learning how to enhance drug selectivity, tackle resistance head-on, and identify optimal combination partners
• Leading the charge in creating first-class kinase-targeted drugs that can ultimately combat disease indications and transform patient outcomes!